The revival of "Intel Inside" is more than a nostalgic nod to the past; it is an effort to underscore Intel's presence in today's interconnected world.

The tagline powering Intel’s brand refresh is "That’s the power of Intel Inside." Unless you’ve been living under a rock (but ...

Intel revives and redefines its iconic 'Intel Inside' campaign with the new slogan 'That's the power of Intel Inside. ' The ...

SAN FRANCISCO, March 17 (Reuters) - Intel's incoming CEO Lip-Bu Tan has considered significant changes to its chip manufacturing methods and artificial intelligence strategies ahead of his return ...

ViiV Healthcare is looking to investigate twice-yearly dosing of its human immunodeficiency virus (HIV) therapy, which has been able to suppress viral load in patients dosed every four months in a ...

ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s EMBRACE phase IIb study.

N6LS was administered in both arms every four months, combined with monthly cabotegravir long-acting injections. Credit: Shutterstock / cawee. ViiV Healthcare is looking to investigate twice-yearly ...

Intel shares are becoming a plaything of the rumor mill. With every new speculation about cooperations or takeovers, the value rises, only to fall again. Recently, the news agency Reuters brought ...

GSK (GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer (PFE) and Shionogi (SGIOY) as shareholders, announced new data from two ...

LONDON--(BUSINESS WIRE)--ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer and Shionogi as shareholders, today announced positive findings from the company’s ...

GSK’s ViiV Healthcare has shared clinical data on three potential long-acting HIV treatments, providing a look at how its plans to create a six-month regimen are shaping up. ViiV, which is ...

ViiV Healthcare, majority owned by GSK (GSK), with Pfizer (PFE) (PE) and Shionogi as shareholders, announced findings from the company’s EMBRACE phase IIb study. The study found that N6LS, given ...